TVTX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

TV

Mkt Cap

$4.68B

Volume

1.30M

Next Earnings

October 29th

Loading chart

TV

TVTXTravere Therapeutics, Inc. Common Stock

TVTX

Pay with—

Available Balance0.00

TV

Mkt Cap

$4.98B

Volume

1.30M

Next Earnings

October 29th

Chart Financials Earnings News About Insider Filings

Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law FirmKuehn Law is investigating whether officers and directors of Travere Therapeutics breached fiduciary duties to shareholders through potential self-dealing. Long-term shareholders may be entitled to damages and corporate governance reforms.GlobeNewswire Inc. · Jul 17, 2026

Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law FirmKuehn Law is investigating whether officers and directors of Rhythm Pharmaceuticals breached fiduciary duties to shareholders through potential self-dealing. Long-term shareholders may be entitled to damages and corporate governance reforms. The law firm is also investigating similar matters at Travere Therapeutics and Viking Therapeutics.GlobeNewswire Inc. · Jul 17, 2026

Validating headline phrasing and editorial resonance A Director Cashes In Near the Top, but What Remains MattersRoy D. Baynes, Director at Travere Therapeutics, exercised and sold 4,500 shares for approximately $210,000 on May 5, 2026, reducing his direct holdings by 10.71%. The sale was executed under a pre-arranged 10b5-1 plan adopted in November 2025 and occurred near the stock's 52-week high. Despite cashing in near the top, Baynes retained 37,500 shares worth ~$1.6 million, suggesting continued conviction in the company.The Motley Fool · May 10, 2026

Your Kidneys Count: American Kidney Fund Urges Americans to Protect Their Health this Kidney MonthThe American Kidney Fund (AKF) is launching its Kidney Month campaign on March 1, 2026, to raise awareness about kidney disease affecting 1 in 7 American adults. The campaign emphasizes early detection and prevention through the 'Kidneys Count' initiative and encourages people to pledge to discuss kidney health with their doctors. AKF will host Kidney Action Week (March 2-5) featuring expert sessions on kidney disease management and treatment options.GlobeNewswire Inc. · Feb 27, 2026

TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Encourages Investors and Potential Witnesses to Contact Law FirmRobbins Geller Rudman & Dowd LLP has launched an investigation into Travere Therapeutics, Inc. for potential violations of U.S. federal securities laws, alleging the biopharmaceutical company and certain executives made materially false and/or misleading statements regarding its business and operations. The firm is seeking investors who suffered losses and potential witnesses to contact them.GlobeNewswire Inc. · Jan 31, 2026

TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law FirmRobbins Geller Rudman & Dowd LLP has launched an investigation into Travere Therapeutics, Inc. for potential violations of U.S. federal securities laws. The investigation examines whether Travere and its executives made materially false or misleading statements regarding the company's business and operations. The law firm is seeking investors who suffered losses and potential witnesses to contact them.GlobeNewswire Inc. · Jan 13, 2026

Why Travere Therapeutics Stock Popped by Nearly 14% on WednesdayTravere Therapeutics stock surged nearly 14% on Wednesday following bullish analyst notes. Jefferies analyst Maury Raycroft identified Travere as a potential takeover candidate and highlighted its drug Filspari as having blockbuster potential. Cantor Fitzgerald reported that the FDA appears flexible on approving Filspari for treating focal segmental glomerulosclerosis (FSGS), with an FDA decision expected by January 13, 2026.The Motley Fool · Dec 24, 2025

Ligand Hosts 2025 Investor Day and Introduces 2026 GuidanceLigand Pharmaceuticals announced 2026 full year revenue guidance of $245-$285 million, representing a 15% core revenue growth, with strong expectations for royalty revenue from key pharmaceutical products.GlobeNewswire Inc. · Dec 9, 2025

American Kidney Fund Hosts Third Patient Access Initiative Summit to Address Barriers to Kidney Care and Propose Innovative SolutionsThe American Kidney Fund hosted its third annual Patient Access Initiative Summit focusing on innovative kidney care technologies, AI applications, and addressing barriers to kidney disease prevention and treatment.GlobeNewswire Inc. · Nov 21, 2025

10 Health Care Stocks With Whale Alerts In Today's SessionMultiple health care stocks experienced significant options trading activity, with various bullish and bearish signals across different companies in the sector.Benzinga · Sep 29, 2025

to start trading

TV

TVTXTravere Therapeutics, Inc. Common Stock

TVTX

Pay with—

Available Balance0.00

Your PositionYou don't own any TVTX yet.

Related Tickers

Earnings